The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions
Open Access
- 23 September 2014
- journal article
- Published by Wiley in Health Economics
- Vol. 24 (10), 1256-1271
- https://doi.org/10.1002/hec.3086
Abstract
The National Institute for Health and Care Excellence (NICE) emphasises that cost-effectiveness is not the only consideration in health technology appraisal and is increasingly explicit about other factors considered relevant but not the weight attached to each. The objective of this study is to investigate the influence of cost-effectiveness and other factors on NICE decisions and whether NICE's decision-making has changed over time. We model NICE's decisions as binary choices for or against a health care technology in a specific patient group. Independent variables comprised of the following: clinical and economic evidence; characteristics of patients, disease or treatment; and contextual factors potentially affecting decision-making. Data on all NICE decisions published by December 2011 were obtained from HTAinSite [www.htainsite.com]. Cost-effectiveness alone correctly predicted 82% of decisions; few other variables were significant and alternative model specifications had similar performance. There was no evidence that the threshold has changed significantly over time. The model with highest prediction accuracy suggested that technologies costing £40 000 per quality-adjusted life-year (QALY) have a 50% chance of NICE rejection (75% at £52 000/QALY; 25% at £27 000/QALY). Past NICE decisions appear to have been based on a higher threshold than £20 000-£30 000/QALY. However, this may reflect consideration of other factors that cannot be easily quantified. © 2014 The Authors. Health Economics published by John Wiley & Sons Ltd.Keywords
Funding Information
- Research grant provided by a consortium of British Pharmaceutical companies: Amgen, AstraZeneca, BMS, Celgene UK & Ireland, GSK, Lilly UK, Merck, Merck Serono, Pfizer, Sanofi Aventis, Schering Plough, Takeda UK, and Wyeth (N/A)
This publication has 20 references indexed in Scilit:
- Decision making by NICE: examining the influences of evidence, process and contextHealth Economics, Policy and Law, 2013
- Reimbursement Decisions of the All Wales Medicines Strategy GroupPharmacoEconomics, 2012
- Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY ProjectHealth Technology Assessment, 2010
- The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004Medical Decision Making, 2008
- Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical ExcellenceJournal of Health Services Research & Policy, 2007
- Deliberative processes and evidence-informed decision making in healthcare: do they work and how might we know?Evidence & Policy, 2006
- NICE's use of cost effectiveness as an exemplar of a deliberative processHealth Economics, Policy and Law, 2006
- “Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-makingHealth Policy, 2005
- Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysisHealth Economics, 2004
- Confidence intervals or surfaces? Uncertainty on the cost-effectiveness planeHealth Economics, 1998